Tag: Alnylam Pharmaceuticals

March 4, 2020

Market Stabilizes After Interest Rate Cut Amid Coronavirus Fears

The S&P 500 and the NASDAQ Composite Index were up nearly 2 percent, while the Dow Jones rose to 2.2...
March 4, 2020

Vir and Alnylam Advance RNAi Therapeutics for COVID-19

Vir and Alnylam announced the development and commercialization of RNAi therapeutics targeting the virus that causes the disease COVID-19.
November 24, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Fulcrum Climbs 73 Percent

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
November 20, 2019

Alnylam Gets FDA Nod for Rare Disease Drug

The FDA's approval of Alnylam's Gilvaari treatment is the first approval of its kind for acute hepatic porphyria.
August 13, 2019

Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ironwood Pharmaceuticals (NASDAQ:IRWD) has announced a US GI disease education and promotional agreement for Alnylam’s givosiran...
January 21, 2019

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an...
October 15, 2018

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),...